Nutra Pharma to Present and Exhibit at Upcoming Investment Conferences in Vancouver, Canada, and Las Vegas, Nevada
Nutra Pharma Has Announced That It Will Be Presenting and Exhibiting at the Upcoming World MoneyShow in Vancouver, Canada, and at the Accredited Members Spring 2010 Small Cap/Micro Cap Investment Conference in Las Vegas, Nevada
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Mar 25, 2010 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be presenting and exhibiting at the upcoming World MoneyShow in Vancouver, Canada, and at the Accredited Members, Inc. Spring 2010 Small Cap/Micro Cap Investment Conference in Las Vegas, Nevada.
“Both the World MoneyShow and the Accredited Members Investment Conference have historically proven to provide excellent venues for building awareness about Nutra Pharma, our drug research, and our recently launched pain relievers, Cobroxin and Nyloxin,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we move through 2010, we plan to continue our outreach efforts and expand our presence within the investment community,” he concluded.
The World MoneyShow, which is scheduled for April 6th through April 8th, will be held at the Hyatt Regency in Vancouver, Canada. The Accredited Members, Inc. Spring 2010 Small Cap/Micro Cap Investment Conference, which is scheduled for April 20th through April 22nd, will be held at the Green Valley Ranch Resort in Las Vegas, Nevada.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above statements pertaining to the World MoneyShow in Vancouver, Canada, and Accredited Members Investment Conference in Las Vegas, Nevada, should not be construed as an indication in any way whatsoever of: (a) the Company's financial value; and/or (b) any predictive value of the Company's future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contact: Nutra Pharma Corporation
David Isserman, 877-895-5647
Posted: March 2010